Onco Actu du 6 décembre 2016

	3.1 Tabac
No safe level of smoking: Even low-intensity smokers are at increased risk of earlier death [NIH] To better understand the effects of low-intensity smoking on mortality from all causes and for specific causes of death, the scientists analyzed data on over 290,000 adults in the NIH-AARP Diet and Health Study. Low-intensity smoking was defined as 10 or fewer cigarettes per day. All participants were age 59 to age 82 at the start of the study.
Take a Number: A New Low for Cigarette Smoking [NY Times] Sixteen percent of men and 14 percent of women smoked in 2015, down from 24 percent and 17 percent in 2005.
Even with one cigarette a day, odds of early death are higher [Reuters] To get a better picture of the health effects of light smoking, researchers tracked more than 290,000 adults aged 59 to 82, including more than 22,000 current smokers and more than 156,000 former smokers, who completed surveys in 2004 and 2005.
	3.2 Prévention - Obésité
The sugar tax: a sweet stocking filler? [Cancer Research UK] We are delighted that the Government is pressing ahead with its sugar tax. It should lead to reduced sugar consumption and healthier soft drink options – all of which will help tackle the growing obesity crisis. But the work is far from over.
UK pushes ahead with sugar tax [BBC News] There will be two bands - one for soft drinks with more than 5g of sugar per 100ml and a higher one for drinks with more than 8g per 100ml. Ministers hope it will help tackle the nation's obesity problem.
	3.8 Prévention - Alimentation
Handful of nuts 'cuts heart disease and cancer' risk [NHS Choices] Overall there does seem to be a link between nut consumption and health, but nuts alone won't reduce your risk of cardiovascular disease or cancers, if your lifestyle is still generally unhealthy.
	4.10 Dép., diag. & prono. - Poumon
App launched to help doctors assess risk of lung cancer in people with lung nodules [Cancer Research UK] Cancer Research UK – in partnership with the British Thoracic Society – used their in-house digital experts to develop a free iOS (iPhone, iPad etc. app for doctors, nurses and technicians examining people with pulmonary nodules.
	5. Traitements
AstraZeneca pill slashes lung cancer progression in study [Reuters] Results published on Tuesday in the New England Journal of Medicine showed that Tagrisso, given as a second-line treatment, helped patients live a median 10.1 months before their cancer worsened, against 4.4 months for those on chemotherapy.
	5.13 WCLC
IASLC WCLC 2016 - Sunday Press Briefing Summary [IASLC] Advocacy and Community Health Care Models Complement Research and Clinical Care World Experts Convene in Vienna, Austria at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer.
ARIAD Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer [Ariad] “We are clearly encouraged by these data that demonstrate efficacy in the brain, with median intracranial PFS of over one and a half years, in patients with crizotinib refractory disease.”
ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations [Celgene] Interim study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in the pivotal Phase III trial.
	5.2.1 Pharma - Partenariats
AbbVie and Johns Hopkins to Collaborate on Cancer Research [AbbVie] Designed to build strong collaboration between AbbVie and Johns Hopkins Medicine researchers, the agreement will focus on several areas of oncology research, which could include lung, colorectal, breast, prostate and hematological cancer.
AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement [AbbVie] "The ability to investigate new therapeutic agents with AbbVie provides us with a great opportunity to expand our translational oncology efforts," said Leonidas C. Platanias, M.D., Ph.D., director of the Lurie Cancer Center.
	5.3 Traitements - FDA, EMA, NICE...
Key FDA official who fought to uphold agency standards to retire [STAT] His Jan. 6 departure will occur as the FDA is expected to come under increasing pressure to relax procedures for approving new medicines and allowing companies to more liberally market their treatments to physicians.
7 ways to make the FDA great again, from a former agency official [STAT] I have been working in investigational drug development for almost two decades. As a politically conservative medical scientist at the FDA — a supreme rarity, I assure you — who has worked as a medical officer and senior medical analyst at the FDA, and as a former investigational medicine research scientist at Pfizer, I haven’t always agreed with regulatory decisions made by the FDA.
	5.4 Traitements - Economie
Global prescription drug spend seen at $1.5 trillion in 2021: report [Reuters] When accounting for anticipated discounts and rebates to health insurers and other payers, 2021 net spending will be closer to $1 trillion, the QuintilesIMS Outlook for Global Medicines through 2021 report found.
	5.8 ASH
Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting [The Street] BCMA is the hot new immunotherapy target for multiple myeloma, and as you'd expect, Celgene is all over it with various approaches, including Bluebird Bio's (BLUE) CAR-T.
	5.8.1 ASH - Communiqués
Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma [Juno] - 80% overall response and 60% complete response - No severe cytokine release syndrome to date and 14% rate of severe neurotoxicity - Side effect profile plus cell persistence suggest potential for combination therapy
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia [Pfizer] Based on the results of the study, Pfizer will work with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to potentially make BOSULIF available for Ph+ CML patients in the first-line setting. Detailed efficacy and safety data from this study will be submitted for a future congress or peer-reviewed journal.
Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting [Seattle Genetics] Long-Term ADCETRIS Data Support Development Strategy to Establish ADCETRIS as Foundation of Care for CD30-Expressing Lymphomas.
Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting [Seattle Genetics] Both Combination and Monotherapy Data Show 33A is Well-Tolerated with Rapid, High Remission Rates for AML Patients in Multiple Phase 1 Trials; Data Highlighted in Three Oral Presentations.
Immunotherapy agent yields full and partial remissions in patients with aggressive non-Hodgkin lymphomas, study finds [Dana-Farber] The research involved five patients with recurrent or refractory primary central nervous system lymphoma (PCNSL) or primary testicular lymphoma (PTL) who were treated with nivolumab, a drug that blocks a key protein, PD-1, on immune system T cells.
Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting [BMS] Data Support Continued Clinical Investigation of ADCETRIS and Opdivo Combination in Hodgkin Lymphoma.
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product [Novartis] Interim data in over 600 adults show potential of GP2013 as an alternative rituximab.
KEYTRUDA® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology [Merck] Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent.
Updated KEYTRUDA® (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology [Merck] Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of Analysis.
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec® [Novartis] ENESTop evaluated stopping Tasigna treatment in eligible Ph+ CML adults with chronic phase disease after they achieved and sustained deep molecular response (MR) for at least one year with Tasigna but had not achieved and sustained this response previously with Glivec.
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work [Novartis] Patients reported a diminished capacity of more than 35% when trying to work, highlighting reduction in quality of life can extend to the workplace.
New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®) [AbbVie] These data supported the recent submission of a supplemental New Drug Application (sNDA) for MZL.
	5.8.3 ASH - Divers
Mutations in lymphoma patients undergoing transplants raise risk of second cancers [Dana-Farber] The mutations were found in about 30 percent of 401 patients with non-Hodgkin lymphoma (NHL) whose blood was sampled at the time they received autologous transplants.
Roche's Gazyva aims to beat blockbuster Rituxan. Can its latest ASH data help? [FierceBiotech] The GALLIUM study is the "first and only Phase III trial to date to show superior progression-free survival compared to MabThera/Rituxan-based treatment, the current standard of care" in previously untreated patients with follicular lymphoma.
GALLIUM turns Gazyva into gold in NHL [OBR] Despite its strong position, Gazyva faces stiff competition. While GALLIUM showed a PFS benefit of Gazyva over Rituxan, the lack of mature OS data may make physicians reluctant to switch to Gazyva, particularly as Rituxan nears the end of its patent lifespan.
Pfizer's blood cancer drug Bosulif effective in untreated patients [Reuters] Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG's Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production.
Study raises questions over benefit of Roche's Gazyva cancer drug [Reuters] In the more-detailed analysis released at the U.S. meeting this weekend, Roche said Gazyva improved progression-free survival by 34 percent among 1,202 patients in the study. But analysts said three-year-old Gazyva's safety profile in combination with bendamustine was a concern, with the rate of severe, life-threatening and fatal adverse events 74.6 percent with Gazyva, versus 67.8 percent with Rituxan.
	5.8.4 ASH - CAR T
Immunotherapy shows promise in preventing leukemia relapse [Fred Hutch] The findings in this group of trial participants contrast with the outcomes the researchers observed in a cohort of similar patients who received transplants around the same time but did not receive engineered T cells.
Can CAR-T cancer treatments be fine-tuned to avoid toxic side effects? [FierceBiotech] A set of researchers at the Fred Hutchinson Cancer Research Center in Seattle who are partially funded by Juno are investigating methods for fine-tuning CAR-T treatments—and they presented early signs of success at ASH.
Juno gets some badly needed relief after a glimpse of upbeat early data on JCAR017 [EndPoints] Twelve of 20 patients who could be evaluated for efficacy in the study of CD19-positive cases of non-Hodgkin lymphoma demonstrated a complete response to the CAR-T therapy following treatment at dose level 1 (5×107 cells).
	5.8.5 ASH - Myélome multiple
Early treatment may prevent progression to multiple myeloma [Dana-Farber] Ghobrial presented data on 47 of the 50 patients enrolled in the study to date, including 23 patients who completed nine treatment cycles. The drug combination caused tumor shrinkage in 82.6 percent of the latter group of patients, with 34.8 percent complete and very good partial responses.
Daratumumab (DARZALEX®) Combination Therapy Showed Consistent Clinical Benefit for Previously-Treated Patients with Multiple Myeloma [Johnson & Johnson] According to a post-hoc analysis of the POLLUX study, daratumumab in combination with lenalidomide (an immunomodulatory agent) and dexamethasone reduced the risk of disease progression or death by 64 percent, compared to lenalidomide and dexamethasone alone, in patients with multiple myeloma who had received one to three prior lines of therapy.
	5.8.6 ASH - Leucémies
Drug combination yields encouraging results in patients with relapsed forms of leukemia or lymphoma in early stage study [Dana-Farber] As of late July, investigators had treated 28 patients – 17 with CLL, 11 with MCL – with the tandem therapy. The regimen was shown to be safe, with an 800 mg dose of TGR-1202 found to be suitable for further study.
Children with Down syndrome and acute lymphoblastic leukemia fare as well as other children treated on Dana-Farber ALL Consortium protocols [Dana-Farber] Researchers studied 1286 diagnosed children and adolescents with ALL treated on the Dana-Farber Consortium protocols between 2000 and 2011 at 11 institutions in the United States, Canada, and Puerto Rico.
A New Antibody For Treating Acute Lymphocytic Leukemia? [Forbes] “These antibodies are terrific drugs,” Kantarjian said. “There’s a lot of excitement about the CAR-T cells. But those are very toxic,” he said. “People may be missing the potential benefit of antibodies.”
	6. Lutte contre les cancers
Cancer Moonshot Resource Center [Elsevier] Free access to research, data, analyses and other resources. By the Elsevier Community.
	6.1 Observation
Suicide in Survivors of Cancer in Childhood, Adolescence and Young Adulthood [ESMO] Survivors of cancer diagnosed before the age of 25 had a more than two-fold increased risk of suicide compared to their non-cancer peers.
	6.10.1 Politiques (USA)
With Nod To Biden, Senate To Say Yes To “Cures” Spending, Reform Bill [Xconomy] The Senate honored Vice President Joe Biden during today’s session by renaming part of the bill after his son, Beau Biden, whose death from brain cancer in 2015 underscored his father’s efforts to create the national “cancer moonshot” program. An emotional Biden presided over the session.
The 21st Century Cures Act: A Giant Piñata [In the Pipeline] In general, it would be hard to vote against a bill that increases cancer funding and efforts against opioid addiction, and a lot of other popular things, but if you can characterize it as an unconscionable giveaway to the drug companies you could probably swing it.
Winners and losers of the 21st Century Cures Act [STAT] Currently the gold standard for testing drugs and devices for safety, the adoption of real world evidence standards may indicate that randomized clinical trials will become less important for drug and device approval.
The 21st Century Cures Act: A huge handout to the drug industry disguised as a pro-research bounty [LA Times] The punchline is that the regulatory rollback is real, but the funding may not be — it’s subject over the next decade to annual appropriations by Congress that might never come.